REVISIONS TO PROFILE AND REFLEX COMPONENTS
Encephalopathy, Autoimmune Evaluation, Serum
Order Code: ENS2
Fee Code: AA267 (CPT 86341), AA268 (CPT 86255) x19
Reference Laboratory: Mayo ENS2
Effective January 31, 2023, there will be additions and deletions to the profile and potential reflex tests for the Encephalopathy, Autoimmune Evaluation, Serum referred to Mayo Clinic Laboratories as follows:
Testing to be added to Profile Information:
• NCDIS: Neurochondrin Antibody, Tissue Immunofluorescence, Serum (CPT 86255)
• SP7IS: Septin-7 Antibody, Tissue Immunofluorescence, Serum (CPT 86255)
Testing to be added to Reflex Tests:
• AGNTS: Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Serum
• AN1TS: Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Serum
• AN2TS: Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Serum
• AN3TS: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Serum
• APHTS: Amphiphysin Antibody Titer Assay, Serum
• CRMTS: Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Serum
• NCDCS: Neurochondrin Antibody, Cell-Binding Assay, Serum
• NCDTS: Neurochondrin Antibody, Tissue Immunofluorescence Titer, Serum
• PC1TS: Purkinje Cell Cytoplasmic Antibody Type 1 (PCA-1) Titer, Serum
• PC2TS: Purkinje Cell Cytoplasmic Antibody Type 2 (PCA-2) Titer, Serum
• PCTTS: Purkinje Cell Cytoplasmic Antibody Type Tr (PCA-Tr) Titer, Serum
• SP7CS: Septin-7 Antibody, Cell-Binding Assay, Serum
• SP7TS: Septin-7 Antibody, Tissue Immunofluorescence Titer, Serum
Testing to be removed from Reflex Tests:
• ARBI: Acetylcholine Receptor (Muscle AChR) Binding Antibody, Serum
Also note new ordering guidelines: This testing is intended to be ordered in adult patients. If this test is ordered on a patient younger than 18 years of age, this test will be cancelled and automatically reordered by the laboratory as Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum (test ID PCDES). Mayo Clinic Laboratories pediatric autoimmune CNS disorders evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.